Lodestone Wealth Management LLC Acquires Stake in BioNTech SE

Lodestone Wealth Management LLC has recently made a significant investment in BioNTech SE (NASDAQ:BNTX). In its latest 13F filing with the Securities and Exchange Commission (SEC), the firm disclosed that it acquired 70,500 shares of BioNTech's stock during the 3rd quarter, with a total investment valued at approximately $8.37 million. This investment now represents 4.1% of Lodestone Wealth Management's overall portfolio, positioning BioNTech as the fund's largest holding.

Institutional Investor Activity

Other large investors have also shown interest in BioNTech, either by increasing their positions or by initiating new ones. Notably, Covestor Ltd increased its stake in BioNTech by 47.2% in the first quarter. After acquiring an additional 133 shares during this period, Covestor now owns 415 shares valued at around $38,000. Similarly, Blue Trust Inc. expanded its investment in the third quarter with a remarkable 491.1% increase, owning 467 shares worth approximately $55,000 after adding 388 shares. Meanwhile, EverSource Wealth Advisors LLC reported a 106.3% increase in its stake, now holding 489 shares valued at $43,000 following an additional purchase of 252 shares. GAMMA Investing LLC also grew its position by 86.9%, acquiring 512 shares worth approximately $41,000 after acquiring 238 more shares. Also noteworthy, Crewe Advisors LLC entered the market for BioNTech shares in the first quarter with a new position approximated at $75,000. Currently, institutional investors hold about 15.52% of BioNTech's shares.

Recent Performance of BioNTech

As of the last trading session, BioNTech stock opened at $111.48. The company boasts a market capitalization of $26.51 billion and operates with a price-to-earnings ratio of -49.33 and a beta of 0.26. Its fifty-day moving average stands at $109.72, while the 200-day moving average is at $95.77. BioNTech has a quick ratio of 7.40 and a current ratio of 7.54, reflecting solid liquidity, alongside a debt-to-equity ratio of 0.01. Over the past year, BioNTech's stock has fluctuated between a low of $76.53 and a high of $131.49.

Analyzing BioNTech's Earnings

BioNTech last reported its quarterly earnings on August 5th and had disappointing results. The company posted earnings per share of ($3.36) for the quarter, significantly missing the analysts' consensus expectation of ($2.02) by $1.34. BioNTech's negative net margin of 18.69% and a negative return on equity of 2.54% highlight ongoing challenges. The revenue for the quarter reached $128.70 million, which also fell short of the consensus estimate of $134.98 million. Compared to the previous year, revenue was down 23.3%. Analysts predict that BioNTech SE will report a loss per share of -2.93 for the current fiscal year.

Changes in Analyst Ratings

Various research firms have provided updates on BioNTech's stock ratings. UBS Group raised its price target from $97.00 to $131.00, maintaining a "neutral" rating on September 18th. JPMorgan Chase & Co. also upgraded the stock to a "neutral" rating, raising its target price from $91.00 to $125.00 on September 16th. TD Cowen lifted its target price from $85.00 to $132.00, issuing a "hold" rating on October 21st. On September 17th, Jefferies Financial Group upgraded BioNTech from a "hold" to a "buy" rating, increasing its target price from $96.00 to $150.00. Lastly, HSBC raised its price target to $136.00 from $97.00, giving BioNTech a "buy" rating on October 7th. The stock currently holds an average rating of "Moderate Buy" with an average price target of $135.54 based on data from analysts.

BioNTech Company Overview

BioNTech SE is a biotechnology company that specializes in developing and commercializing immunotherapies for cancer and infectious diseases. The firm is actively working on several product candidates, including BNT111 for advanced melanoma (currently in Phase II trials), BNT112 for prostate cancer (in Phase I/IIa trials), and BNT113 for HPV 16+ head and neck cancers (in Phase II trials), among others.

investment, BioNTech, stocks